Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

CR-000172

News Release

 View printer-friendly version

Charles River Laboratories Celebrates 5 Years on New York Stock Exchange

WILMINGTON, Mass.--(BUSINESS WIRE)--June 13, 2005--Charles River Laboratories, Inc. (NYSE: CRL) announces that James C. Foster, Chairman, President and CEO of the Company will be ringing the bell to close trading on the New York Stock Exchange on Monday, June 13, 2005, at 4 p.m. EDT. The bell ringing is in recognition of the Company's 5 years of trading on the NYSE. Following his ringing of the closing bell, Mr. Foster is scheduled to conduct a live broadcast interview on CNBC's "Closing Bell with Maria Bartiromo" at 4:40 p.m. EDT.

In light of this event, Mr. Foster stated: "We welcome this opportunity to celebrate our 5 years of trading on the Exchange. This period of time has truly been transformational for the Company. Outsourcing continues to be a more strategic opportunity for our pharmaceutical and biotech customers. And, our diverse portfolio of products and services allows us to partner with our customers across the entire drug pipeline from earliest compound identification to market approval. From December 2000 to December 2004, our revenues have grown by 150% to $767 million and we have moved from a loss of $11.2 million to net income of $89.8 million; we have 100 facilities in 20 countries and have completed 8 acquisitions since going public in June 2000. We look forward to continued growth and closer collaborations with our customers moving forward."

About Charles River Laboratories

Charles River Laboratories, based in Wilmington, Massachusetts, is a global provider of solutions that advance the drug discovery and development process. Our leading-edge products and services are designed to enable our clients to bring drugs to market faster and more efficiently. Backed by our rigorous, best-in-class procedures and our proven data collection, analysis and reporting capabilities, our products and services are organized into three categories spanning every step of the drug development pipeline: Research Models and Services, Preclinical Services, and Clinical Services. Charles River's customer base includes all of the major pharmaceutical companies, and many biotechnology companies, government agencies and leading hospitals and academic institutions. Charles River's 8,000 employees serve clients in more than 50 countries. For more information on Charles River, visit our website at www.criver.com.

CONTACT: Charles River Laboratories, Inc.
Elizabeth Ferber, 978-658-6000 ext. 1693
Director, Corporate Communications
corpcomm@criver.com

SOURCE: Charles River Laboratories, Inc.

Featured Report

2018 Annual Report (PDF)

Investor Hotline

877-567-6CRL (6275)